To gain a better understanding of the anti-tumor mechanisms underlying combination therapy and the role of STAT1 in TCL, we transfected STAT1 shRNA into H9 and Karpas 299 cells, confirming effective STAT1 knockdown via qPCR and Western blot analysis (Fig. 4E and Supplementary Fig. S6A, B). The gene discussed is STAT1; the disease is neoplasm.